Filing Details

Accession Number:
0001209191-21-033984
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-19 16:04:22
Reporting Period:
2021-05-17
Accepted Time:
2021-05-19 16:04:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557290 A Stuart Arbuckle C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Comm & Ops Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-05-17 7 $215.33 41,205 No 4 S Direct
Common Stock Disposition 2021-05-17 86 $216.36 41,119 No 4 S Direct
Common Stock Disposition 2021-05-17 16 $217.15 41,103 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 140 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $215.33 (range $214.82 to $215.80).
  3. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $216.36 (range $215.82 to $216.76).
  5. Open market sales reported on this line occurred at a weighted average price of $217.15 (range $216.83 to $217.32).